이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

2015년 3월 20일 업데이트: AstraZeneca

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months

Patients initiating injectable therapy for type 2 diabetes (insulin or exenatide) in usual clinical practice will be enrolled and followed up for two years in order to describe actual practice with regards to the time on initial treatment regime, whether treatment regimens are being modified, what treatment modifications are made, and clinical and patient-reported outcomes.

연구 개요

상태

완전한

정황

개입 / 치료

연구 유형

관찰

등록 (실제)

2515

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 그리스
      • Kozani, 그리스
        • Research Site
      • N. Efkarpia, 그리스
        • Research Site
      • Thessaloniki, 그리스
        • Research Site
      • Veroia, 그리스
        • Research Site
  • 덴마크
      • Amager, 덴마크
        • Research Site
      • Ronne, 덴마크
        • Research Site
  • 독일
      • Alsfeld, 독일
        • Research Site
      • Aschaffenburg, 독일
        • Research
      • Asslar, 독일
        • Research Site
      • Augsburg, 독일
        • Research Site
      • Bad Aibling, 독일
        • Research Site
      • Bad Homburg, 독일
        • Research Site
      • Bad Mergentheim, 독일
        • Research Site
      • Bergheim, 독일
        • Research Site
      • Berlin, 독일
        • Research Site
      • Birkenfeld, 독일
        • Research
      • Bosenheim, 독일
        • Research Site
      • Bruchsal, 독일
        • Research Site
      • Dortmund, 독일
        • Research Site
      • Dresden, 독일
        • Research Site
      • Duisburg, 독일
        • Research Site
      • Eberswalde, 독일
        • Research Site
      • Eilenburg, 독일
        • Research Site
      • Eisenach, 독일
        • Research Site
      • Erfurt, 독일
        • Research Site
      • Essen, 독일
        • Research Site
      • Frankfurt, 독일
        • Research Site
      • Gebhardshain, 독일
        • Research Site
      • Gersfeld, 독일
        • Research Site
      • Giessen, 독일
        • Research Site
      • Gifhorn, 독일
        • Research Site
      • Grassau, 독일
        • Research Site
      • Gross-Gerau, 독일
        • Research Site
      • Hadmersleben, 독일
        • Research Site
      • Halle, 독일
        • Research Site
      • Hamburg, 독일
        • Research Site
      • Hammelburg, 독일
        • Research Site
      • Hennigsdorf, 독일
        • Research Site
      • Hohenmolsen, 독일
        • Research Site
      • Ismaning, 독일
        • Research Site
      • Kothen, 독일
        • Research Site
      • Kutenholz, 독일
        • Research Site
      • Langen, 독일
        • Research Site
      • Langenfeld, 독일
        • Research Site
      • Leipzig, 독일
        • Research Site
      • Lichtenfels, 독일
        • Research Site
      • Ludwigsburg, 독일
        • Research Site
      • Luneburg, 독일
        • Research Site
      • Marburg, 독일
        • Research Site
      • Mayen, 독일
        • Research Site
      • Meissen, 독일
        • Research Site
      • Minden, 독일
        • Research Site
      • Monchengladbach, 독일
        • Research Site
      • Munchen, 독일
        • Research Site
      • Munster, 독일
        • Research Site
      • Nassau, 독일
        • Research Site
      • Netphen, 독일
        • Research Site
      • Oberhausen, 독일
        • Research Site
      • Pirmasens, 독일
        • Research Site
      • Recklinghausen, 독일
        • Research Site
      • Rehburg-Loccum, 독일
        • Research Site
      • Reichenbach, 독일
        • Research Site
      • Riesa, 독일
        • Research Site
      • Saarbrucken, 독일
        • Research Site
      • Saarlouis, 독일
        • Research Site
      • Schkeuditz, 독일
        • Research Site
      • Schonwalde, 독일
        • Research Site
      • Schweinfurt, 독일
        • Research Site
      • Seligenstadt, 독일
        • Research Site
      • Siegen, 독일
        • Research Site
      • Stockach, 독일
        • Research Site
      • Thale, 독일
        • Research Site
      • Ubach-Palenberg, 독일
        • Research Site
      • Ueckermunde, 독일
        • Research Site
      • Villingen-Schwenningen, 독일
        • Research Site
      • Volklingen, 독일
        • Research Site
      • Warburg, 독일
        • Research Site
      • Weissenberg, 독일
        • Research Site
      • Werl, 독일
        • Research Site
      • Westfalica, 독일
        • Research Site
      • Wilhelmshaven, 독일
        • Research Site
      • Wurzen, 독일
        • Research Site
  • 스웨덴
      • Angelholm, 스웨덴
        • Research Site
      • Angered, 스웨덴
        • Research Site
      • Dalby, 스웨덴
        • Research Site
      • Falun, 스웨덴
        • Research Site
      • Goteborg, 스웨덴
        • Research Site
      • Limhamn, 스웨덴
        • Research Site
      • Lulea, 스웨덴
        • Research Site
      • Malmo, 스웨덴
        • Research Site
      • Skivarp, 스웨덴
        • Research Site
      • Skovde, 스웨덴
        • Research Site
      • Stockholm, 스웨덴
        • Research Site
      • Vadstena, 스웨덴
        • Research Site
      • Vastervik, 스웨덴
        • Research Site
  • 프랑스
      • Toul Cedex, 프랑스
        • Research Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

The study population consisted of patients aged 18 or above, with type 2 diabetes starting any of the available initial injectable treatment options (any insulin, or exenatide BID) for the treatment of type 2 diabetes as part of routine clinical care.

설명

Inclusion Criteria:

  • are aged 18 or above
  • diagnosed with type 2 diabetes
  • have had a treatment decision made within the normal course of care to initiate either insulin or exenatide for the treatment of type 2 diabetes
  • have not previously been treated with either insulin or exenatide
  • are not simultaneously participating in another study which includes an investigational drug or procedure at study entry
  • have been fully informed and given their written consent for use of their data
  • have sufficient understanding of the primary language of their country such that they will be able to complete the questionnaires.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
1
exenatide
의약품: 엑세나타이드
피하 주사, 5mcg 또는 10mcg, 하루에 두 번
다른 이름들:
  • 비에타
2
insulin
의약품: any human insulin or analog insulin(s) given in any regimen by subcutaneous injection

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Estimates of Probability to Remain on Initial Injectable Treatment at 12 and 24 Months.
기간: Month 24

The primary objective of this study is to estimate the time spent on initial treatment regime before significant treatment change for patients with type 2 diabetes initiating therapy with either insulin or exenatide for the first time.

Initial treatment regime is defined as the treatment regime prescribed when the patient is enrolled in the study.

Significant treatment change for patients initiated on insulin or exenatide is defined as at least one of the following:

Insulin:

  • Addition of a new medication for the treatment of type 2 diabetes
  • A change in the number of times insulin is administered per day
  • Discontinuation of any insulin initiated at baseline
  • Substitution of a human insulin for an analogue insulin or vice-versa.
  • Switching between brands of the same class/type of insulin is not included in the definition of significant treatment change.

Exenatide:

  • Addition of a new medication for the treatment of type 2 diabetes
  • Discontinuation of exenatide.
Month 24

2차 결과 측정

결과 측정
측정값 설명
기간
Higher Body Mass Index (BMI) Associated With Treatment Choice at Baseline
기간: Baseline
Higher BMI was one of the Factors evaluated for association with treatment choice at baseline. BMI was calculated as body weight in kilograms (kg) divided by height in meters (m) squared (kg/m^2). The mean BMI at baseline is provided below and the statistical analysis provides the 2 arms odds ratio for BMI=1 kg/m^2 higher. Participants were assigned to the exenatide BID or insulin cohort based the injectable treatment started at baseline; analyses were conducted irrespective of later treatment changes. Baseline was Visit T1 (prior to start of treatment).
Baseline
Higher Hemoglobin A1c (HbA1) Associated With Treatment Choice at Baseline
기간: Baseline
Higher HbA1c was one of the Factors evaluated for association with treatment choice at baseline.HbA1c was reported in percent of hemoglobin. The mean HbA1c at baseline is provided below and the statistical analysis provides the 2 arms odds ratio for HbA1c=1% higher.
Baseline
Older Age Associated With Treatment Choice at Baseline
기간: Baseline
Older age (1 year older) was one of the Factors evaluated for association with treatment choice at baseline. The mean age at baseline is provided below and the statistical analysis provides the 2 arms odds ratio for age 1 year older. Participants were assigned to the exenatide BID or insulin cohort based the injectable treatment started at baseline; analyses were conducted irrespective of later treatment changes. Baseline was Visit T1 (prior to start of treatment).
Baseline
Disinhibited Eating Associated With Treatment Choice at Baseline
기간: Baseline
Diabetes Health Profile (DHP-18) - consists of 18 items across 3 domains (psychological distress, barriers to activity, and disinhibited eating), with each item standardized score rated from 0-100; 0=no dysfunction, higher numbers=greater dysfunction. The subscale of disinhibited eating was one of the Factors evaluated for association with treatment choice at baseline. The number of participants with disinhibited eating at baseline is provided below and the statistical analysis provides the 2 arms odds ratio for disinhibited eating. Participants were assigned to the exenatide BID or insulin cohort based the injectable treatment started at baseline; analyses were conducted irrespective of later treatment changes. Baseline was Visit T1 (prior to start of treatment).
Baseline
Higher Random Glucose Associated With Treatment Choice at Baseline
기간: 6 months prior to Baseline
Random Glucose 1 millimole per liter (mmol/L) higher was one of the Factors evaluated for association with treatment choice at baseline. Random glucose is a glucose within the last 6 months prior to baseline. The mean is provided below and the statistical analysis provides the 2 arms odds ratio for the glucose 1 mmol/L higher. Participants were assigned to the exenatide BID or insulin cohort based the injectable treatment started at baseline; analyses were conducted irrespective of later treatment changes. Baseline was Visit T1 (prior to start of treatment).
6 months prior to Baseline
Frequent Blood Glucose Self Monitoring Associated With Treatment Choice at Baseline
기간: 4 weeks prior to Baseline
Frequent glucose self-testing (1 test/week more) was one of the Factors evaluated for association with treatment choice at baseline. The mean number of self monitoring blood glucose tests per week over the last 4 weeks prior to baseline was determined at baseline and is provided below. The statistical analysis provides the 2 arms odds ratio. Participants were assigned to the exenatide BID or insulin cohort based the injectable treatment started at baseline; analyses were conducted irrespective of later treatment changes. Baseline was Visit T1 (prior to start of treatment).
4 weeks prior to Baseline
Diet and Exercise Advice in Diabetes Management Associated With Treatment Choice at Baseline
기간: Baseline
Receipt of diet and exercise advice was one of the Factors evaluated for association with treatment choice at baseline. The number of participants who checked yes or no during the baseline visit for prior receipt of diet/exercise advice in his/her Diabetes management is provided below and the statistical analysis provides the 2 arms odds ratio. Participants were assigned to the exenatide BID or insulin cohort based the injectable treatment started at baseline; analyses were conducted irrespective of later treatment changes. Baseline was Visit T1 (prior to start of treatment).
Baseline
Higher Value of Low Density Lipoprotein Cholesterol Associated With Treatment Choice at Baseline
기간: Baseline
Higher (1 mmol/L higher) LDL cholesterol was one of the Factors evaluated for association with treatment choice at baseline. The mean LDL cholesterol at baseline is provided below and the statistical analysis provides the 2 arms odds ratio for 1 mmol/L higher at baseline. Participants were assigned to the exenatide BID or insulin cohort based the injectable treatment started at baseline; analyses were conducted irrespective of later treatment changes. Baseline was Visit T1 (prior to start of treatment).
Baseline
Changes in HbA1c From Baseline to Month 24
기간: Baseline, Month 24
Changes in HbA1c From Baseline to Month 24
Baseline, Month 24
Percentage of Patients Achieving HbA1c Concentration <7.0% at Month 24
기간: Month 24
Percentage of Patients Achieving HbA1c Concentration <7.0% at Month 24. Only patients with baseline HbA1c >= 7.0 % were included in this analysis
Month 24
Percentage of Patients Achieving HbA1c Concentration <6.5% at Month 24
기간: Month 24
Percentage of Patients Achieving HbA1c Concentration <6.5% at Month 24. Note: Only patients with baseline HbA1c >=6.5% were included in this analysis.
Month 24
Changes in Weight From Baseline to Month 24
기간: Baseline, Month 24
Changes in Weight From Baseline to Month 24
Baseline, Month 24
Incidence of Gastro Intestinal Symptoms Between Baseline and 24 Months
기간: Baseline to Month 24
Incidence of Gastro Intestinal Symptoms between Baseline and 24 Months
Baseline to Month 24
Incidence of Hypoglycemia Between Baseline and 24 Months
기간: Baseline to Month 24
Incidence of Hypoglycemia between Baseline and 24 Months
Baseline to Month 24
Reasons for Discontinuation of Baseline Regimen
기간: Baseline to Month 24
Reasons for Discontinuation of Baseline Regimen
Baseline to Month 24
Factors Associated With Treatment Change in Insulin Cohort
기간: Baseline to Month 24
Hazards ratios from Backward Cox Regression Model for time to significant treatment change in Insulin cohort
Baseline to Month 24
Factors Associated With Treatment Change in Exenatide BID Cohort
기간: Baseline to Month 24
Hazards ratios from Backward Cox Regression Model for time to significant treatment change in Exenatide BID cohort. EQ-5D (Health Questionnaire Copyright @ Euro QoL Group 1998).
Baseline to Month 24
Percentage of Patients Contacting Health Care Providers Between Baseline and 24 Months
기간: Baseline to Month 24
Percentage of Patients Contacting Health Care Providers Between Baseline and 24 Months
Baseline to Month 24
Number of Contacts With Health Care Providers Between Baseline and 24 Months
기간: Baseline to Month 24
Number of contacts with Health Care Providers Between Baseline and 24 Months
Baseline to Month 24
Percentage of Patients Hospitalized Between Baseline and 24 Months
기간: Baseline to Month 24
Percentage of Patients Hospitalized Between Baseline and 24 Months
Baseline to Month 24

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

AstraZeneca

협력자

Eli Lilly and Company

수사관

  • 연구 책임자: James Malone, MD, Eli Lilly and Company

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2008년 1월 1일

기본 완료 (실제)

2011년 12월 1일

연구 완료 (실제)

2011년 12월 1일

연구 등록 날짜

최초 제출

2008년 2월 20일

QC 기준을 충족하는 최초 제출

2008년 3월 12일

처음 게시됨 (추정)

2008년 3월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2015년 4월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2015년 3월 20일

마지막으로 확인됨

2015년 3월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • H8O-EW-B005

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다